DNA polymerase δ, whose catalytic subunit is encoded by POLD1, is responsible for lagging-strand DNA synthesis during DNA replication 1 . It carries out this synthesis with high fidelity owing to its intrinsic 3′- to 5′-exonuclease activity, which confers proofreading ability. Missense mutations affecting the exonuclease domain of POLD1 have recently been shown to predispose to colorectal and endometrial cancers 2 . Here we report a recurring heterozygous singlecodon deletion in POLD1 affecting the polymerase active site that abolishes DNA polymerase activity but only mildly impairs 3′- to 5′-exonuclease activity. This mutation causes a distinct multisystem disorder that includes subcutaneous lipodystrophy, deafness, mandibular hypoplasia and hypogonadism in males. This discovery suggests that perturbing the function of the ubiquitously expressed POLD1 polymerase has unexpectedly tissue-specific effects in humans and argues for an important role for POLD1 function in adipose tissue homeostasis.
Progressive loss of subcutaneous adipose tissue, or lipodystrophy, with concomitant severe insulin resistance is a major feature of the recently described mandibular hypoplasia, deafness and progeroid features (MDP) syndrome 3 . Defining the genetic basis of this newly described form of progressive partial lipodystrophy would provide insights into the regulation of adipose tissue. Several genetic causes of partial lipodystrophy have previously been described 4 . Some of these affect genes with established roles in adipocyte differentiation or function, including PPARG, PLIN1 and CIDEC. However, for other commonly implicated genes, including LMNA and ZMPSTE24, the link between the cellular defect and the adipose phenotype is poorly understood 4 . The mechanism underlying selective loss of only some adipose depots across all these conditions is also currently unclear.
Because all reported individuals with MDP syndrome have unrelated parents and no other affected family members, we hypothesized that the syndrome was caused by a heterozygous de novo mutation in a single gene. We therefore performed exome sequencing on two probands with MDP syndrome ( Fig. 1 and Supplementary Table 1) and their unaffected parents to look for candidate de novo diseasecausing mutations. Exonic sequences were enriched from genomic DNA using the Agilent SureSelect Human All Exon kit (version 4) and then sequenced on an Illumina HiSeq 2000 sequencer using 100-bp paired-end reads. We used Burrows-Wheeler aligner (BWA v0.6.2) 5 to align sequence reads to the hg19 reference genome and the Genome Analysis Toolkit (GATK v2.2-10) 6 to call single-nucleotide variants (SNVs) and indels. We covered 88% of targeted bases at >20×.
We identified an in-frame deletion (c.1812_1814delCTC, p.Ser605del) of a single codon in POLDI affecting the polymerase active site in both probands but in none of the four parents. We confirmed these results by Sanger sequencing (Online Methods). The c.1812_1814delCTC variant is absent from dbSNP137, the 1000 Genomes Project 7 and the Exome Variant Server 8 . We then screened two additional individuals with MDP syndrome by Sanger sequencing and identified an identical in-frame deletion in both subjects. These findings provide convincing genetic evidence that the mutation encoding p.Ser605del is the disease-causing mutation in these four unrelated cases.
The most prominent phenotype of all four affected individuals was lack of subcutaneous adipose tissue, which was first noted in early childhood, although each proband was born with normal birth weight and appearance (Supplementary Table 1 ). The minimal subcutaneous adipose tissue at all sites contrasted with the marked increase in visceral adipose tissue ( Fig. 1 and Supplementary Table 1) . The ratio of visceral to subcutaneous adipose tissue was greatly elevated at 15.21 in subject 1 with MDP syndrome in contrast to the median 9 4 8 VOLUME 45 | NUMBER 8 | AUGUST 2013 Nature GeNetics l e t t e r s value of 0.84 (interquartile range of 0.64-1.10) in 1,680 middle-aged men 9 . All affected individuals had clinical and biochemical evidence of insulin resistance, despite having body mass index (BMI) values of <20 kg/m 2 . Other common clinical features included skin scleroderma and telangiectasia, ligament contractures, reduced mass of limb muscles, mandibular hypoplasia, hypogonadism and undescended testes in males, and sensorineural deafness (Supplementary Table 1 ). None of the affected individuals in our relatively young series or in a previous report 3 has been diagnosed with cancer.
DNA polymerase δ has been shown to cooperate with WRN, a DNA helicase, to help maintain genome stability 10 . Loss of WRN function in humans leads to Werner syndrome, which presents with the premature onset of features associated with normal aging 11 DNA replication is fundamental to the successful division of all nucleated cells, and POLD1, which encodes the catalytic subunit of the key, processive lagging-strand polymerase, thus serves a ubiquitous and critical cellular function 1 . Correspondingly, knockout of the mouse ortholog Pold1 does not result in viable animals 14 . The tissuespecific effect of the heterozygous deletion mutation we have found is thus unexpected. POLD1 mRNA was well expressed across a panel of human tissues, including muscle and fat, but differential expression did not account for the phenotype (Supplementary Fig. 1 ). Moreover, there was no evidence in the commonly used mouse 3T3-L1 model of adipogenesis that Pold1 expression changed during the differentiation of preadipocytes into fat cells (Supplementary Fig. 2 ).
Subcutaneous abdominal adipose tissue from subject 1 (BMI of 19.1 kg/m 2 ) showed abundant fibrosis dividing the remaining fat tissue but no obvious inflammatory cell infiltrates ( Fig. 1 and Supplementary  Fig. 3 ). Consistent with this observation, the expression levels of key extracellular matrix genes were markedly different from those in five lean controls (BMI values of 20.0-21.8 kg/m 2 ), with increased expression of transforming growth factor (TGF)-β (TGFB1), a hallmark of tissue fibrosis, and markedly higher expression of fibronectin (FN1) (Supplementary Fig. 4 ). Increased fibrosis has been correlated with adipose tissue dysfunction and insulin resistance in a variety of settings, including in individuals with lipodystrophy due to PLIN1 mutations 15 and common obesity 16 . 
t t e r s
The Ser605 deletion occurs in motif A, a highly conserved region of the polymerase δ catalytic subunit. This motif comprises 11 amino acids that are involved in the alignment of the incoming complementary dNTP with the primer terminus, as well as in the coordination and catalysis of phosphodiester bond formation 17 . Alterations in this domain have been shown to affect base selection and, consequently, polymerase fidelity in nearly every family of DNA polymerases from viruses to mammals 18, 19 . In silico modeling predicted that the Ser605 deletion profoundly affects the structure of the polymerase active site, in particular, by disrupting the hydrogen bonding between the substrate trinucleotide and the catalytic aspartate residues. As a comparison, the predicted structure of the catalytic site and bonding to the trinucleotide substrate were identical to those of wild-type POLD1 for both Pro327Leu and Ser478Asn mutants (data not shown). The proofreading domain was not predicted to be affected, in contrast to the expected changes previously reported for the cancer-predisposing mutations 2 (Fig. 2 and Online Methods). We therefore hypothesized that the Ser605del mutant polymerase would be able to bind DNA but not catalyze polymerization.
To test this hypothesis, we generated the Ser605 deletion mutant by PCR-mediated mutagenesis and purified the four-subunit human DNA polymerase δ holoenzyme from Escherichia coli (Online Methods). We quantified the polymerase activity of the purified enzyme by measuring primer elongation on a 23-nt primer-46-nt template duplex in the presence of all four dNTPs (Fig. 3a) . Under conditions in which wild-type polymerase δ (150 fmol) extended 81% of the primer, DNA extension using the same amount of the mutant enzyme was not detected.
To assess the exonuclease activity of polymerase δ with wild-type and Ser605del mutant POLD1, we adapted the extension assay by excluding dNTPs. The exonuclease activity of the wild-type enzyme was linear in reactions using 30, 90 and 150 fmol of enzyme, and comparison of the amount of primer degradation using different amounts of mutant enzyme (90, 150 and 300 fmol) against this linear range showed that polymerase δ with Ser605del POLD1 had 1.7-to 2.5-fold lower exonuclease activity than wild-type polymerase (Fig. 3b) . Despite this difference, the exonuclease activity of the mutant polymerase δ enzyme was considerable. Collectively, these findings demonstrate decoupling of the enzymatic activities of the mutant enzyme. Its preserved exonuclease activity indicates that it can bind DNA and suggests that the inability to extend DNA primers is due to an inability to efficiently interact with and incorporate dNTPs.
These results provide a possible molecular explanation for the markedly different phenotype caused by the Ser605 deletion compared to the previously described cancer predisposition mutations 2 . Whereas the cancer-related mutations affect the proofreading domain and lead to increased base-substitution error rates 2 , we show that polymerase δ with Ser605del POLD1 can bind to DNA but not catalyze polymerization. This is likely to result in an increase in stalled replication forks, which are associated with double-stranded DNA breaks, genomic instability, cell cycle checkpoint response and cell senescence and death 20 . Preserved DNA binding by the mutant also raises the possibility that it may be able to compete with coexpressed wild-type polymerase, and previous work in yeast has shown that reduction in the amount of DNA polymerase δ leads to increased numbers of deletions and genomic instability 21, 22 . However, further work is required to understand how the mutation encoding the Ser605 deletion leads to the specific phenotype observed in the affected individuals with MDP syndrome.
There is some support for the notion of distinct phenotypes caused by mutations affecting different POLD1 domains from mouse models. Mice harboring a homozygous mutation in Pold1 encoding p.Asp400Ala in the proofreading domain showed a tenfold increase in the base-substitution error rate over wild-type mice, and 94% of these mice developed cancer by the age of 18 months 23 . In contrast, mice with a heterozygous substitution encoding p.Leu604Lys (equivalent to human p.Leu606Lys and neighboring the Ser605 residue deleted in individuals with MDP syndrome) showed an 18% reduction in lifespan, a small increase in tumorigenesis and a clear increase in chromosome aberrations 19 . Subsequent work suggested that this phenotype is due to an increase in the incidence of stalled replication forks, particularly at sites of DNA damage 24 . Lipodystrophy was not reported in mice expressing the p.Leu604Lys mutant; however, it has proved very challenging to replicate other forms of partial lipodystrophy in mice, which may require extreme caloric loads to manifest metabolic disease 25 .
In conclusion, whereas missense mutations of POLD1 affecting the proofreading domain predispose to cancer, we show that a singlecodon deletion in POLD1 affecting the polymerase active site causes a markedly different phenotype that includes lipodystrophy. We further show that this mutation results in complete loss of polymerase activity but very little loss of exonuclease capacity. In addition to aiding in a b 
ONLINe MeTHODs
Subjects. Individuals with MDP syndrome were identified by their clinicians and referred for molecular genetic analysis in the Exeter Molecular Genetics Laboratory. All subjects gave informed consent for genetic testing, and the study was approved by the North Wales Research Ethics Committee.
Exome sequencing. Exonic sequences were enriched from genomic DNA using Agilent's SureSelect Human All Exon kit (version 4) and then sequenced on an Illumina HiSeq 2000 sequencer using 100-bp paired-end reads. We used BWA (v0.6.2) 5 to align sequence reads to the hg19 reference genome and GATK (v2.2-10) 6 to call SNVs and indels.
Sanger sequencing confirmation. We amplified POLD1 exon 15 using the primers whose sequences are listed in Supplementary Table 2 . PCR products were sequenced on an ABI3730 capillary machine (Applied Biosystems) and analyzed using Mutation Surveyor v3.98 (SoftGenetics).
Protein modeling. The sequence of full-length POLD1 was submitted for automated modeling and template selection using the SWISS-MODEL web interface. This returned a structure for POLD1 residues 77-983 based on template 3iay, chain A (Saccharomyces cerevisiae DNA polymerase δ, catalytic subunit; 49% sequence identity), which was the same template used for the model of human POLD1 in the Protein Model Portal database (P28340). Subsequently, all modeling of mutant sequences was carried out using template 3iay (chain A), and structures were visualized in the Swiss-PdbViewer.
Human tissue expression profiling.
A human tissue whole-RNA panel was purchased from AMS Biotechnology and was provided by L. Tung. cDNA synthesis was performed using the ImProm-IITM Reverse Transcription System (Promega) according to the manufacturer's recommendation. Human POLD1 mRNA and 18S rRNA levels were determined using TaqMan Gene Expression assays (Hs01100821_m1 for POLD1 and custom designed for 18S (sequences available upon request); Applied Biosystems). Serially diluted human cDNA was used to generate a standard curve for each assay, and all RNA determinations were performed in duplicate using TaqMan PCR Master Mix on an ABI 7900 detection system (Applied Biosystems). POLD1 mRNA expression levels were normalized to the levels of 18S rRNA for comparison between tissues.
3T3-L1 differentiation time course. 3T3-L1 cells (American Type Culture Collection) were cultured in DMEM supplemented with 10% NCS, 100 U/l penicillin, 100 µg/ml streptomycin, 4 mM l-glutamine and 4 mg/ml puromycin (Sigma) in a humidified incubator with 5% CO 2 at 37 °C. Preadipocyte differentiation was induced by growing cells for 2 d after they reached confluence and exposing them to medium in which FBS replaced NCS that was supplemented for the first 3 d with 500 µM IBMX, 1 µM dexamethasone (Sigma-Aldrich) and 100 nM soluble human insulin (Novo Nordisk) and for the next 3 d with 100 nM insulin only, with no supplements thereafter. Total RNA was extracted using an RNeasy mini kit (Qiagen) at the time points indicated. mRNA levels of Pold1 were determined using an inventoried TaqMan Gene Expression assay (Hs01100821_m1; Applied Biosystems), and levels of Adipoq and cyclophilin A were determined using custom-designed TaqMan Gene Expression assays (sequences available upon request). Quantitative RT-PCR assays were undertaken as described, and mRNA levels for the genes of interest were normalized to those of cyclophilin A (PPIA) for comparison. Three time courses were undertaken in duplicate. Results shown are the mean levels with s.e.m. from these biological replicates.
Expression and fibrosis studies from fat. Abdominal subcutaneous adipose tissue biopsies were obtained from subject 1 (BMI of 19.1 kg/m 2 ) from below and lateral to the umbilicus and from five healthy, lean controls of European ancestry (BMI range of 20.0-21.8 kg/m 2 ) obtained during elective surgery and with consent and ethical approval from the NIHR Exeter Tissue Bank. Biopsies were immediately snap frozen in liquid nitrogen and stored at −80 °C until processing. Total RNA was extracted using the phenol-chloroformguanidinium-thiocyanate method 26 . Briefly, ~100 mg of tissue was homogenized in TRI reagent (Life Technologies) using a Retsch Mixer Mill MM400 in accordance with the manufacturer's instructions, and RNA concentrations were determined spectrophotometrically using Nanodrop technology. RNA was treated with DNase to remove residual genomic contamination, and 500 ng was reverse transcribed in a random-primed single-strand synthesis reaction using high-capacity reverse transcriptase (Life Technologies).
cDNA was diluted 1:20 in 0.01 M Tris-HCl, and amplification was performed using Universal PCR Master Mix (Life Technologies) and extracellular matrix gene-specific probes (probe sequences available upon request). All samples were amplified in triplicate for each assay and were run alongside a standard curve to allow assay efficiency determination. Samples amplified in the absence of reverse transcriptase enzyme and samples without template were used as negative controls. Amplification was performed using an ABI 7900 thermal cycler with the following cycling parameters: 50 °C for 2 min, 95 °C for 10 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Gene expression levels were calculated using the 2 −∆∆CT analysis method modified by Pfaffl 27 , normalizing to the levels of the adipose-specific housekeeping genes PPIA and UBC 28 .
For fibrosis studies, fat tissue biopsies from subject 1, as well as from a lean individual (BMI of 20 kg/m 2 ) and an obese individual (BMI of 43.6 kg/m 2 ) obtained during elective surgery, were formalin fixed, paraffin embedded and stained with picrosirius red (Sigma-Aldrich) for fibrosis as previously described 16 .
MRI. Abdominal images were collected via an MRI T1 (spin-lattice relaxation time)-weighted breath-hold sequence to obtain images with high fat contrast. Subcutaneous and visceral fat volumes were calculated via semi-automated processing based on signal intensity thresholding between the L5/S1 disk and the bottom of the lung.
Site-directed mutagenesis. The 3-nucleotide deletion was introduced into the pET303-hpold1 plasmid 29 using 5′-phosphorylated primers flanking the deletion site (Supplementary Table 3) . PCR products were gel purified and ligated before transformation into XL10-Gold Ultracompetent Cells (Stratagene). A region between the AgeI and ClaI sites of POLD1 was amplified and sequence verified, and this region was then subcloned back into AgeI-and ClaI-digested pET303-hpold1 vector that had not been PCR amplified.
Purification of polymerase δ with Ser605del POLD1. The mutant polymerase δ holoenzyme was purified as described 30 . Briefly, the pET303-hpold1 plasmid and the pCOLA-2, pCOLA-3 and pCOLA-4 plasmids, with sequences encoding the p66, p55 and p12 subunits of the polymerase δ holoenzyme, respectively, were cotransformed into BL21-tRARE cells by electroporation. Protein expression was induced in mid-log phase cells by the addition of β-d-1-thiogalactopyranoside (IPTG). Cells were sonicated, and the crude extract was subjected to nickel column (Novagen) chromatography in which polymerase δ was bound via the polyhistidine tag on the p12 subunit. Bound enzyme was eluted with 300 mM imidazole and was further purified by ion exchange chromatography on a HiTrap SP HP column (GE) using a linear (0.2-1.0 M) NaCl gradient.
Polymerase and exonuclease assays. The polymerase and exonuclease activities of wild-type polymerase δ and polymerase δ with Ser605del mutant POLD1 were measured using the same reaction mixtures and enzyme dilutions. Reactions included the indicated concentrations of enzyme, 40 mM Tris-HCl (pH 7.4), 4 mM MgCl 2 , 0.1 mg/ml BSA, 5 mM DTT, 25 µM each dNTP (polymerase reactions only) and 10 nM 5′ end-labeled primer-template DNA duplex (Supplementary Table 4 ). Reactions were incubated for 2 min at 37 °C and stopped by the addition of 95% formamide in 20 mM EDTA. Samples were resolved on a 14% polyacrylamide TBE-urea gel; reaction products were visualized following imaging on a PhosphorImager (Molecular Dynamics) and analyzed using ImageJ64 software.
